Glancy
Prongay & Murray LLP (“GPM”) announces an investigation on
behalf of investors of NantKwest, Inc. (“NantKwest” or the “Company”)
(NASDAQ: NK)
concerning the Company and its officers’ possible violations of federal
securities laws in connection with alleged accounting errors in the
Company’s financial statements. GPM is preparing a lawsuit on behalf of
injured investors.
NantKwest is a biotechnology company that develops immunotherapeutic
agents for various clinical conditions. The investigation concerns
NantKwest’s March 11, 2016 announcement that the Company's interim
financial statements, for the quarters ended June 30, 2015 and September
30, 2015, should not be relied upon due to financial statement errors in
connection with certain stock-based awards. The Company also announced
that NantKwest’s financial statements contained errors related to
build-to-suit lease accounting.
On this news, shares of NantKwest fell over 3% on March 11, 2016,
closing at just $8.17 per share.
If you purchased NantKwest securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley
Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los
Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20160412006355r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160412006355/en/
Copyright Business Wire 2016